Significant & clinically meaningful improvement in distant metastasis-free survival with Keytruda in patients with resected stage IIB or IIC melanoma in phase III KEYNOTE-716 trial.
Merck Inc., announced distant metastasis-free survival (DMFS) results from the Phase III KEYNOTE-716 trial investigating Keytruda, Merck’s anti-PD-1 therapy, versus placebo as adjuvant therapy for patients with resected stage IIB or IIC melanoma.
With a median follow-up of 27.4 months, Keytruda demonstrated a statistically significant and clinically meaningful improvement in DMFS versus placebo (HR=0.64 [95% CI, 0.47-0.88]; p=0.0029). Median DMFS was not reached in either arm. These late-breaking data are being presented for the first time today at 10:45 a.m. ET during an oral abstract session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (abstract #LBA9500).
Additionally, at the median 27.4-month follow-up, Keytruda continued to show a reduction in the risk of recurrence versus placebo (HR=0.64 [95% CI, 0.50-0.84]). According to Kaplan-Meier estimates, 81.2% of patients in the Keytruda arm were recurrence-free at two years compared to 72.8% of patients in the placebo arm. A prespecified exploratory analysis of health-related quality of life (HRQoL) from KEYNOTE-716 will also be presented at ASCO 2022 on Monday, June 6 (abstract #9581), showing HRQoL was similar between the Keytruda and placebo arms based on EORTC Quality of Life Questionnaire Core 30 or EQ-5D-5L VAS scores.
“Patients with stage IIB and IIC melanoma are at risk of seeing their cancer return and spread to distant sites,” said Dr. Georgina Long, co-medical director, Melanoma Institute Australia (MIA), and chair, Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, University of Sydney. “The latest results from KEYNOTE-716 show the potential of pembrolizumab to help reduce distant recurrence in patients with resected stage IIB and IIC melanoma, and further highlight the important role of adjuvant therapy for these patients.”
In the study, the safety profile of Keytruda was consistent with previously reported studies in patients with solid tumors, and no new safety signals were observed at the time of DMFS analysis. Treatment-related adverse events Grade 3 or higher were observed in 17% of patients receiving Keytruda versus 5% of patients receiving placebo. Immune-mediated events and infusion reactions were higher with Keytruda (38% vs 9%, respectively).
“Based on survival data, we know that patients with stage IIB and IIC melanoma have similar five-year outcomes as those with stage IIIB melanoma,” said Dr. Scot Ebbinghaus, vice president, global clinical development, Merck Research Laboratories. “In KEYNOTE-716, treatment with Keytruda after surgery improved both distant metastasis-free survival and recurrence-free survival compared to placebo in patients with stage IIB or IIC melanoma. These data are encouraging for the melanoma community and add to results from six positive pivotal studies for Keytruda-based regimens in earlier stages of cancer.”
In addition to KEYNOTE-716, the five other pivotal trials evaluating a Keytruda-based regimen in patients with earlier stages of cancer met their primary endpoint(s). These trials include: KEYNOTE-091 in stage IB ( greater than 4 centimeters) to IIIA non-small cell lung cancer; KEYNOTE-054 in stage III melanoma; KEYNOTE-564 in renal cell carcinoma; KEYNOTE-522 in triple-negative breast cancer; and KEYNOTE-057 in Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins